Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral Immunotherapy for Wheat Allergy

Trial Profile

Oral Immunotherapy for Wheat Allergy

Phase of Trial: Phase I/II

Latest Information Update: 19 May 2018

At a glance

  • Drugs Wheat Allergy immunotherapy-DBV Technologies (Primary)
  • Indications Food hypersensitivity
  • Focus Therapeutic Use
  • Acronyms Wheat OIT
  • Most Recent Events

    • 14 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 24 Mar 2017 New trial record
    • 06 Mar 2017 Primary end point (The percentage of desensitized participants as measured by the ability to consume at least 4443 mg of wheat protein during a 7443 mg wheat protein Oral Food Challenge (OFC) performed 1 year after initiating treatment) has been met ,according to the results published at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top